Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 7 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study

  • Andrew Haydon1
  • Jose Lutzky2
  • Siwen Hu-Lieskovan3
  • Drew Rasco4
  • Meredith McKean5
  • Nehal Lakhani6
  • Ganessan Kichenadasse7
  • Vinod Ganju8
  • Sophia Frentzas9
  • Andrew Weickhardt10
  • Aron Knickerbocker11
  • Yanay Ofran12
8 more authors
  • Jenny Tang11
  • Lori Richards11
  • Paul de Souza13
  • John D Powderly14
  • Eric Lander15
  • Jeffrey T Yorio16
  • Timothy L Wyant17
  • James R Vasselli18
18 affiliations
  1. 1The Alfred Hospital, Melbourne, VIC, Australia
  2. 2University of Miami, Sylvester Cancer Center, Miami, FL, USA
  3. 3Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA
  4. 47START San Antonio, San Antonio, TX, USA
  5. 51Sarah Cannon Research Institute, Nashville, TN, USA
  6. 69 START Midwest, Grand Rapids, Michigan, USA
  7. 711Southern Oncology Clinical Research Unit, Bedford Park, SA, Australia
  8. 8Peninsula and South East Oncology, Frankston, VIC, Australia
  9. 92Department of Medical Oncology, Monash Health, Clayton, VIC, Australia
  10. 10Austin Health, Heidelberg, VIC, Australia
  11. 1115Aulos Bioscience, Larkspur, CA, USA
  12. 1216Biolojic Design, Rehovot, Israel
  13. 13Southside Cancer Care, Miranda, NSW, Australia
  14. 14Carolina BioOncology Institute, PLLC, Huntersville, NC, USA
  15. 15Minnesota Oncology and Hematology, Minneapolis, MN, USA
  16. 16Texas Oncology, Austin, TX, USA
  17. 17Biolojic Design Inc, Cambridge, MA, USA
  18. 18Aulos Bioscience, San Francisco, CA, USA
Open at sourcePDFDOICite

Related

  1. 605 Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)
    Drew Rasco, Meredith McKean, Ramaswamy Govindan +15
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. Marked Response to Nivolumab Plus Ipilimumab After the Failure of Two Prior Immune Checkpoint Inhibitor–Based Regimens Including CTLA-4 Blockade in Advanced Hepatocellular Carcinoma
    Shinichiro Minami, Wataru Sato, Kenjiro Yamamoto +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedGeneral medicineJ-STAGE
  3. 270 AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
    Nils-Petter Rudqvist, Bishnu Joshi, Dhan Chand +8
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. Corticosteroid-refractory checkpoint inhibitor pneumonitis in lung cancer: biological heterogeneity and mechanism-informed management
    Rong Zhang, Xiaoxue Zhang, Xiulan He +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0OncologyCrossref
  5. Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial
    Roxane Riemer, Lukas M. Braun, Sophie Giesler +43
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{haydon2026imneskibart,
  title = {{611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study}},
  author = {Andrew Haydon and Jose Lutzky and Siwen Hu-Lieskovan and Drew Rasco and Meredith McKean and Nehal Lakhani and Ganessan Kichenadasse and Vinod Ganju and Sophia Frentzas and Andrew Weickhardt and Aron Knickerbocker and Yanay Ofran and Jenny Tang and Lori Richards and Paul de Souza and John D Powderly and Eric Lander and Jeffrey T Yorio and Timothy L Wyant and James R Vasselli},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0611},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0611},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study
AU  - Andrew Haydon
AU  - Jose Lutzky
AU  - Siwen Hu-Lieskovan
AU  - Drew Rasco
AU  - Meredith McKean
AU  - Nehal Lakhani
AU  - Ganessan Kichenadasse
AU  - Vinod Ganju
AU  - Sophia Frentzas
AU  - Andrew Weickhardt
AU  - Aron Knickerbocker
AU  - Yanay Ofran
AU  - Jenny Tang
AU  - Lori Richards
AU  - Paul de Souza
AU  - John D Powderly
AU  - Eric Lander
AU  - Jeffrey T Yorio
AU  - Timothy L Wyant
AU  - James R Vasselli
PY  - 2026
DA  - 2026/11/07
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0611
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0611
SN  - 2051-1426
ER  -